ISSN 1662-4009 (online)

ey0020.10-9 | Metabolic Syndrome | ESPEYB20

10.9. The association of metabolic syndrome status with sensorineural hearing loss in pediatric obese patients

O Ozdemir , A Ucar , AD Cakir , E Misir , O Yigit

Brief summary: This study assessed the relation between the metabolic syndrome (MetS) and sensorineural hearing loss in children with obesity. Children with MetS were shown to have subclinical hearing loss compared to those without MetS.Comment: Associations between obesity and hearing loss have been reported in several adult studies.1 However, similar studies in adolescents have yielded conflicting results. The present study aimed to address ...

ey0017.11-1 | Corona and Obesity | ESPEYB17

11.1. Obesity could shift severe COVID-19 disease to younger ages

DA Kass , P Duggal , O Cingolani

To read the full abstract: Lancet 2020;395(10236):1544–45.This study tested the association between age and BMI using data from patients (n =265) with COVID-19 infection treated at the intensive care units at 6 US University Hospitals. Results show a significant inverse correlation between age and BMI in this sample. Interestingly, adolescents and young adults were more likely...

ey0016.5-11 | Clinical Guidance | ESPEYB16

5.11. Autoimmune polyendocrine syndromes

ES Husebye , MS Anderson , O Kampe

Abstract: N Engl J Med. 2018 Jun 28;378(26):2543–2544.In brief: This article reviews important developments and major advances in characterizing autoimmunity in patients with autoimmune polyendocrine syndromes, such as the identification of new autoantibody targets associated with distinct diseases and their manifestations. The authors also provide an up to date review...

ey0018.1-13 | Clinical/Translational | ESPEYB18

1.13. Anterior pituitary function in Rathke's cleft cysts versus nonfunctioning pituitary adenomas

M Fujii , A Nakagawa , O Tachibana , H Iizuka , D Koya

Endocr J. 2021 Apr 3. doi: 10.1507/endocrj.EJ21-0050. PMID: 33814485.Mizue Fujii and colleagues retrospectively evaluated the pituitary function in 67 and 111 adult patients with Rathke’s cleft cyst (RCC) and non-functioning pituitary adenoma (NFA), respectively. The study population represented consecutive patients encountered in their institute. They found that RCCs were smaller t...

ey0021.15-13 | New Paradigms | ESPEYB21

15.13. Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study

K Johansson , LM Bodnar , O Stephansson , B Abrams , JA. Hutcheon

In Brief: The population-based Stockholm-Gotland Perinatal Cohort study analysed electronic medical records on 15 760 pregnancies with obesity, followed up for a median of 7.9 years. In pregnancies with class 1 or 2 obesity, low gestational weight gain (GWG, mean 0 kg at 40 weeks) did not increase risk of the adverse composite outcome (class 1: adjusted RR 0.97 [95% CI 0.89–1.06]; class 2: 0.96 [0.86–1.08]). In pregnancies with class 3 obesity, low GWG (mean 0 kg at ...

ey0021.1-12 | New Treatments and Hopes | ESPEYB21

1.12. Insights into central congenital hypothyroidism: A multicenter retrospective analysis

A German , S Almashanu , Vries L de , Margolis M Gil , R Halloun , A Haim , O Eyal , F Levy-Khademi , D Pivko-Levy , J Nir , O Pinhas-Hamiel , Y Tenenbaum-Rakover

Brief Summary: This multicentre retrospective cross-sectional study provides critical insights into the epidemiology, clinical presentation, and neurodevelopmental outcomes of central congenital hypothyroidism (CCH).CCH is a rare disorder that occurs due to insufficient hypothalamic-pituitary stimulation of the thyroid, characterized by low total T4 (TT4) with either low, normal or slightly elevated TSH. Most newborn screening (NBS) programs for CH are p...

ey0018.13-13 | Endocrinology | ESPEYB18

13.13. Aetiologies and clinical patterns of hypopituitarism in Sudanese children

SS Hassan , R Mukhwana , S Musa , AAB Ibrahim , O Babiker , MA Abdullah

Sudan J Paediatr 2021;21:53–60. doi: 10.24911/SJP.106-1588448825– This paper describes the characteristics of 156 children and adolescents with hypopituitarism from 2 hospitals in Sudan– Congenital causes (86.5%) were more prevalent than acquired causes (13.5%)– Consanguinity was found in 77.8% of patients overall and 91% of patients with congenital aetiologies. The...

ey0018.14-1 | (1) | ESPEYB18

14.1. Association of vitamin D levels, race/ethnicity, and clinical characteristics with COVID-19 test results

Meltzer David O , Best Thomas J , Zhang Hui , Vokes Tamara , Arora Vineet M , Solway Julian

JAMA Netw Open. 2021;4(3):e214117. https://bit.ly/3zopFZ4This prospective observational cohort study (n=4638) measured vitamin D level in the year before undergoing COVID-19 testing. The risk of a positive COVID-19 test in Black, but not White, individuals was 2.64-fold higher if vitamin D level was 30–40 ng/ml compared to > 40 ng/ml.Vitamin D may improve immune functi...

ey0019.3-3 | Thyroid hormone action | ESPEYB19

3.3. Extended absorption of liothyronine from poly-zinc-liothyronine: results from a phase 1, double-blind, randomized, and controlled study in humans

AM Dumitrescu , EC Hanlon , M Arosemena , O Duchon , M Ettleson , M Giurcanu , AC Bianco

Thyroid. 2022 Feb;32(2):196-205. doi: 10.1089/thy.2021.0304. Epub 2021 Dec 31. PMID: 34641706Brief Summary: This phase 1, double-blind, randomized, single-dose, placebo-controlled, crossover study compared pharmacokinetics, pharmacodynamics, incidence of adverse events, and sleep pattern between the routinely used L-triiodothyronine (LT3) and a newly developed metal-coordinated form of LT3 (pol...

ey0019.4-4 | Important for clinical practice | ESPEYB19

4.4. Effects of growth hormone treatment on sleep-related parameters in adults with Prader-Willi syndrome

HH Shukur , L Hussain-Alkhateeb , Farholt S , O Norregaard , AP Jorgensen , C Hoybye

The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 9, e3634–e3643PMID: 33950234Brief Summary: This trial explored the effects of rhGH treatment in patients with Prader-Willi syndrome (PWS) on respiratory and sleep parameters. The trial was randomized and placebo-controlled for 1 year, followed by a 2-year, open-phase GH treatment period. Polysomnography performed every 6 months revealed no adverse effects of rhGH tr...